Leukemias: Related News

Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Scientists from Memorial Sloan-Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.

In the future, more-advanced genetic testing might offer better ways to match up patients who need a bone marrow transplant with potential donors.

Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).

German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.

A study led by researchers at Memorial Sloan-Kettering and New York University has shown that TET2 loss enhances the function of blood stem cells, causing them to renew themselves more efficiently than normal blood stem cells.

A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.